Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp > Publication

<< Previous

Bullboard Posts

Next >>

Post by Jesus4Prezon Feb 27, 2021 9:34am

310 Views

Post# 32678477

Publication

I emailed IR to ask if they had any very rough timeline when the third party Covid study results might be published (Don had mentioned seeing some very positive results, yet to be published).

The reply I received was simple , but encouraging "Updates will be released via news release, we anticipate being able to share this in the near future."

<< Previous

Bullboard Posts

Next >>

Investing with insurance and protection